NOVAN INC (NOVN)
(Delayed Data from NSDQ)
$1.22 USD
+0.07 (5.75%)
Updated May 3, 2019 03:59 PM ET
After-Market: $1.22 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[NOVN]
Reports for Purchase
Showing records 1 - 20 ( 100 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Exploring Marketed Drugs Sale, Focusing on SB206, 50% RIF (Mostly Sales)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
Industry: Medical - Drugs
1Q23: Temporary Fade in RHOFADE Sales Fixed, SB206 Likely Approved Jan ''24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
KOL Call Highlights That Likely Favorable Market Dynamics Await KINSOLUS
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
Industry: Medical - Drugs
4Q22: Strong 4Q22 Prescription Growth, Expecting 1Q24 KINSOLUS Approval
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
SB206 (KINSOLUS) Long-Awaited NDA for Molluscum Filed; Project 1Q24 Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Sato Licenses RHOFADE Development and Commercial Rights In Japan
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
3Q22: Expect SB206 NDA Filing by January; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q22: Expected Seasonal Product Rev Drop, Kinsolus NDA Filing Around YE22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
Industry: Medical - Drugs
Survey Shows Patients Value Attributes Like Those Possessed By Wynzora
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Industry: Medical - Drugs
2Q22: Recently Acquired Commercial Business Pays for Itself While SB206 On Track for Year-End NDA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Drugs
2Q22: Recently Acquired Commercial Business Pays for Itself While SB206 On Track for end-2023 NDA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Drugs
2Q22: Growth in Promoted Product Sales, Kinsolus NDA Expected By YE22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J